<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912349</url>
  </required_header>
  <id_info>
    <org_study_id>2020-525</org_study_id>
    <nct_id>NCT04912349</nct_id>
  </id_info>
  <brief_title>Comparison of TUSP Versus TURP for Treatment of Benign Prostatic Hyperplasia in a Small Prostate Volume</brief_title>
  <official_title>Comparison of Transurethral Split of the Prostate Versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia in a Small Prostate Volume: A Prospective Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of transurethral split of the prostate versus transurethral resection of the&#xD;
      prostate for treatment of benign prostatic hyperplasia in a small prostate volume: A&#xD;
      prospective controlled study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transurethral resection of the prostate (TURP) was considered as the golden standard to treat&#xD;
      benign prostatic hyperplasia (BPH) for decades. However, TURP was associated with low&#xD;
      efficiency to alleviate the lower urinary tract symptoms and a significantly higher risk of&#xD;
      bladder neck contracture (BNC) for patients with small-volume BPH. We aimed to compare the&#xD;
      therapeutic effect of transurethral split of the prostate (TUSP) with TURP for patients with&#xD;
      small-volume BPH (&lt;30 ml).&#xD;
&#xD;
      In this study, some selected small-volume BPH patients were randomly divided into two groups&#xD;
      (TUSP and TURP group). The patient's baseline characteristics and perioperative outcomes were&#xD;
      recorded. The follow-up was made at 6 months, 1 year and 2 years after surgical treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>international prostate symptoms score（IPSS）</measure>
    <time_frame>within 24 months after surgery</time_frame>
    <description>Measuring the International Prostate Symptoms Score by a questionnaire (which minimum value is zero and the maximum value is 35; higher scores mean a worse outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum urinary flow rate（Qmax）</measure>
    <time_frame>within 24 months after surgery</time_frame>
    <description>Measuring the maximum urinary flow rate by a urodynamic study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received the transurethral split of the prostate(TUSP) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received the transurethral resection of the prostate(TURP) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TUSP</intervention_name>
    <description>Patients received the transurethral split of the prostate(TUSP) treatment.</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TURP</intervention_name>
    <description>Patients received the transurethral resection of the prostate(TURP) treatment.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Benign prostatic hyperplasia patients with surgical indication&#xD;
&#xD;
          -  Maximum flow rate &lt;12ml/s&#xD;
&#xD;
          -  Prostate volume &lt;30ml&#xD;
&#xD;
          -  The international prostate symptoms score&gt;21&#xD;
&#xD;
          -  Medication of α-adrenergic blockers for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute prostatitis and urethritis&#xD;
&#xD;
          -  Neurogenic bladder&#xD;
&#xD;
          -  Abnormal prostate-specific antigen level&#xD;
&#xD;
          -  Urethral injury history&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiaming Wen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiaming Wen, Dr.</last_name>
    <phone>+86-571-87783550</phone>
    <email>wenjiaming@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiaming Wen, Dr.</last_name>
      <phone>+86-571-87783550</phone>
      <email>wenjiaming@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

